Immutep (ASX:IMM) announced the initiation of the Phase III TACTI-004 clinical trial, which aims to evaluate the efficacy of its lead immunotherapy candidate, eftilagimod alfa (“efti”), in the first-line treatment of non-small cell lung cancer (NSCLC) metastatic.
Efti will be used in combination with Merck’s Keytruda (pembrolizumab) and chemotherapy. This will be compared to standard Keytruda treatment with chemotherapy (and a placebo).
The randomized, double-blind study will enroll approximately 750 patients with metastatic NSCLC and will be conducted in more than 150 clinical centers in over 25 countries.
The study will measure two primary endpoints: progression-free survival and overall survival.
Marc Voigt, CEO of Immutep, commented: “This…represents a critical step towards potentially establishing a new standard of care for patients with metastatic NSCLC. Based on the strength of the data from eftilagimod alfa we are confident that it can do a significant difference in the lives of cancer patients, and we look forward to enrolling the first patient in this important study during the first quarter of 2025.”
Yesterday the stock closed up 1.49% at 34 cents.